semaglutide y tirzepatide Outperforms in Blood Sugar Control Comparative safety and side effects

Vazquez-Martin, A., Oliveras-Ferraros, C., Del, B

Whit Bernard, Metsera CEO Metseras long-acting GLP-1 looks competitive in Phase 2 obesity study Data from a mid-stage obesity trial of Metseras long-acting injectable GLP-1 agonist suggest it could be competitive with approved incretins and several investigational compounds

Timing Matters: Splitting the dosage throughout the day may improve absorption

What Our Patients Are Saying New Regenerative Injections for Your Elbow Plasma injection for tennis elbow and golfers elbow belong to the emerging field of regenerative treatments

TB 500 promotes the recruitment of reparative cells in stress-induced laboratory models